Abstract:Key Points A large fraction of point mutations that cause genetic diseases affect splicing efficiency and/or accuracy. Most of these mutations directly affect the canonical consensus sequences that define exon–intron boundaries, and are therefore correctly identified as 'splicing mutations'. Information that is present in the coding regions of genes also contributes to the correct identification of exon–intron boundaries. For example, exonic splicing enhancer (ESE) and silencer (ESS) elements are very prevalent and might be present in most, if not all, constitutive and alternative exons. ESEs are recognized by a class of splicing factors, the SR proteins, that promote splicing by recruiting spliceosomal components to the correct splice sites and/or by antagonizing the action of nearby silencers. Several classes of ESEs, which are recognized by different SR proteins, have been identified, and computational tools are being developed to predict the location, specificity and efficiency of putative ESEs. Because ESEs are embedded in protein-coding sequences, some nonsense, missense and translationally silent point mutations have actually been misclassified. Those mutations that inactivate an ESE can result in partial or complete exon skipping, and can therefore markedly affect the structure or amounts of the expressed protein product. An increasing proportion of point mutations are being reported to affect pre-mRNA splicing. Although reading-frame-dependent mechanisms have been proposed to account for nonsense-associated altered splicing (NAS), in most cases the disruption of ESEs or of RNA secondary structures that are required for proper splicing seems to be the mechanism that leads to exon skipping, regardless of the type of point mutation. Some coding single-nucleotide polymorphisms (cSNPs) can be expected likewise to disrupt elements that are involved in splicing and to exert a subtle effect on splice-site selection, thereby contributing to phenotypic variability, to the variable penetrance of mutations elsewhere in the gene and to cell-type-specific differences in gene expression. The effects of point mutations should be routinely analysed at the mRNA level before drawing conclusions about the importance of the affected amino acid, as their correct classification in terms of the actual mechanism of gene inactivation is essential for understanding structure–function relationships in the corresponding protein, for assessing the phenotypic risk in individuals with familial disease predispositions and for devising new therapies.

ESEfinder: a Web Resource to Identify Exonic Splicing Enhancers.

The eukaryotic translation initiation factor eIF4E reprograms alternative splicing

ExonImpact: Prioritizing Pathogenic Alternative Splicing Events.

Human Splicing Finder: an online bioinformatics tool to predict splicing signals

Systematic characterization of short intronic splicing-regulatory elements

Systematic characterization of short intronic splicing-regulatory elements in SMN2 pre-mRNA

SeeSite: Efficiently Finding Co-occurring Splice Sites and Exon Splicing Enhancers

Computational Analysis Reveals a Correlation of Exon-Skipping Events with Splicing, Transcription and Epigenetic Factors.

Genomic features defining exonic variants that modulate splicing

Listening to silence and understanding nonsense: exonic mutations that affect splicing

Identification Exon Skipping Events from High-Throughput RNA Sequencing Data

Model-Based Prediction Of Cis-Acting Rna Elements Regulating Tissue-Specifc Alternative Splicing

Features of missense/nonsense mutations in exonic splicing enhancer sequences from cancer-related human genes.

Systematically developing a registry of splice-site creating variants utilizing massive publicly available transcriptome sequence data

One-Size-Fits-Many: Antisense oligonucleotides for rescuing splicing mutations in hotspot exons

Computational Identification of Tissue-Specific Splicing Regulatory Elements in Human Genes from RNA-Seq Data

Missense Mutations of MLH1 and MSH2 Genes Detected in Patients with Gastrointestinal Cancer Are Associated with Exonic Splicing Enhancers and Silencers.

Regulation of Splicing Enhancer Activities by RNA Secondary Structures

Comprehensive splicing analysis of the alternatively spliced CHEK2 exons 8 and 10 reveals three enhancer/silencer‐rich regions and 38 spliceogenic variants

The deep intronic c.903+469T>C mutation in the MTRR gene creates an SF2/ASF binding exonic splicing enhancer, which leads to pseudoexon activation and causes the cblE type of homocystinuria

Coordinated alternative splicing decisions via stepwise exon definition